- Email: [email protected]
Abstracts Accepted for Oral Presentation
Clinical Oncology (2002) 14: S33–S35 doi:10.1053/clon.2002.0130, available online at http://www.idealibrary.com on
The Annual Scientific Meeting of the BOA in Association with BASO
Cancer Research in the New NHS Robinson College, Cambridge Sunday 1st – Tuesday 3rd September, 2002
ABSTRACTS ACCEPTED FOR ORAL PRESENTATION Monday 2nd September 2002 The Challenge for Cancer in the Next Decade – A1 Auditorium, 09:00–10:00 R Black Progress in Cancer in the United Kingdom P Boyle Progress in Cancer in Europe: Challenges for the Next Decade
A1.1 A1.2
Proffered Papers – A2 Auditorium, 10:00–11:00 T Maughan N Lester G Laking D Routsis
How Does Investment in Research Networks Affect Cancer Research Activity? Establishing National Cancer Research Networks – Organisation, Structure and Impact ‘‘REFSARCH’’, A Test of the Tests for Cancer Hypoxia Measuring the Impact of New Radiotherapy Technologies on Treatment Times
A2.1 A2.2 A2.3 A2.4
An Integrated Information Environment for Translational Cancer Research Trials and Tribulations of Clinical Research: The Multi-Professional Team Approach Out Patient Site Specialist Nurses Improve Clinical Trial Recruitment A Model of Linear Accelerator Capacity
B1.1 B1.2 B1.3 B1.4
Proffered Papers – B1 Umney Theatre, 10:00–11:00 S Nagl H Moore S Khanduri N Burnet
Ethics: The Patient’s Role in Cancer Research – A3 Auditorium, 11:30–13:00 R Thomas M Robling J Tobias M King M Baum
Increasing User Involvement in Clinical Trials – Validating Patient Preference as a Legitimate Endpoint? Collecting Data for Disease Registries Without Patient Consent: What Do The Public Think? Research Governance – What Does the Cancer Clinician Need to Know About it? The Patient’s Contribution to Cancer Research The Patient’s Role in Cancer Research
A3.1
Should Primary Colorectal Cancer Excision be Avoided in Patients with Liver Metastases? The MRC Myeloma VII Trial of Standard Versus Intensive Treatment in Patients <65 Years of Age with Multiple Myeloma Randomised Trial of Standard 2D Radiotherapy (RT) Versus 3D Intensity Modulated Radiotherapy (IMRT) in Patients Prescribed Breast Radiotherapy A National Overview of Lung Cancer Surgery in Scotland
B2.1 B2.2
A3.2 A3.3 A3.4 A3.5
Proffered Papers – B2 Umney Theatre, 11:30–12:30 A Hanna-Morris G Morgan J Yarnold A Kirk
B2.3 B2.4
S34 New Technologies – A4 Auditorium, 14:00–16:00 C Caldas M van de Vijver D Miles C Nutting P Price T McCullough
Molecular Profiling in Cancer Care Microarray Analysis in Breast Cancer Targeted Systemic Therapies for Cancer New Technology in Radiation Oncology PET Scanning in Oncology When is PT-PCR Identification of Circulating Tumour Cells in Patients Undergoing Primary Colorectal Cancer Resection Most Predictive of Recurrence?
A4.1 A4.2 A4.3 A4.4 A4.5 A4.6
MRI Scanning in Breast Cancer Screening The ProtecT Study Should We Try To Screen for Lung Cancer? A Cohort Study into the Symptoms of Colorectal Cancer Using a General Practice Database 2% of Men With Early Onset Prostate Cancer Harbour Deleterious Germline Mutations in the BRCA2 Gene
B3.1 B3.2 B3.3 B3.4
Talking About Randomised Clinical Trials: An Interactive Workshop Describing Randomisation: Patients’ and Public’s Preferences Compared with Clinicians Practice
C1.1 C1.2
Prevention and Screening – B3 Umney Theatre, 14:00–15:30 R Warren F Hamdy M Meurs R Lawrenson R Eeles
B3.5
Talking About Trials – C1 Breakout Room 1, 14:00–16:00 L Fallowfield V Jenkins
NCRI Breast Cancer Workshop – A5 Auditorium, 16:30–17:45 J Stefoski-Mikeljevic J Yarnold P Hopwood I Kunkler
Does Postoperative Radiotherapy Delay in Breast Cancer Matter? Fractionation Sensitivity of Change in Breast Appearance after Radiotherapy for Early Breast Cancer: Long-Term Results of a Randomised Trial Quality of Life (QL) in Women Treated for Early Stage Breast Cancer Entering the START (Standardisation of Breast Radiotherapy) Trial PRIME – Trial Postoperative Radiotherapy in Low Risk Elderly Patients: SUPREMO – Selective Use of Postoperative Radiotherapy after Mastectomy in Intermediate Risk Breast Cancer Patients (2 abstracts combined)
A5.1 A5.2
Magnetic Resonance Imaging and Rectal Cancer European Equivalence Study (The M.E.R.C.U.R.Y. Study) The Use of the Pelican Surgical Training Programme to Improve Outcomes for Rectal Cancer in Trent Region The Teseract Trial: Target Selected Randomised Trial of Novel Therapies in Colorectal Cancer
B4.1
A5.3 A5.4
NCRI Colorectal Workshop – B4 Umney Theatre, 16:30–17:30 I Daniels N Armitage T Maughan
B4.2 B4.3
NCRI Lung Cancer Workshop – C2 Venue: Breakout Room 1, 16:30–18:00 M Saunders M Hatton R Stephens
M Hatton E Denholm
CHARTWEL with Neo-Adjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) A Randomised Trial of Megesterol Acetate and Prednisolone for Anorexia/Weight Loss in Patients with Lung Cancer and Mesothelioma The Big Lung Trial (BLT): Determining the Value of Cisplatin-Based Chemotherapy for all Patients with Non-Small Cell Lung Cancer (NSCLC). Preliminary Results in the Supportive Care Setting A Proposed Randomised Phase III Study of Induction Chemotherapy and CHARTWEL versus CHART Alone in Locally Advanced Non-Small Cell Lung Cancer The MARS (Mesothelioma and Radical Surgery) Trial
C2.1 C2.2 C2.3
C2.4 C2.5
S35 NCRI Urology Workshop – D1 Breakout Room 2, 16:30–17:30 E Hall M Leahy
R Huddart
A Phase III Randomised Trial of Post-Radiotherapy Intermittent Androgen Suppression (IAS) for Prostate Cancer Patients with Rising PSA – Survey of Interest The EMI Study: A Regional Feasibility Study for a Randomised Trial of Adjuvant Chemotherapy Following Definitive Treatment for Transitional Cell Carcinoma of the Bladder BC2001 – A Randomised Trial of Chemo-Radiotherapy in Bladder Cancer
D1.1 D1.2
D1.3
Tuesday 3rd September 2002 Educational Workshop – A6 Auditorium, 08:00–09:00 M Parmar
Trial Design
A6
Adjuvant Chemotherapy in Elderly Patients with Breast Cancer
B5
Educational Workshop – B5 Umney Theatre, 08:00–09:00 B Leonard
Cancer Research in the UK – a Blueprint for the Future? – A7 Auditorium, 09:00–12:20 R Hamilton A Spaull L O’Toole P Selby D Kerr R Souhami M Richards
The NHS Strategy for Cancer Research Supporting Cancer Research in Scotland NCRI Strategy and Future Plans The National Cancer Research Network – Scientific Opportunities National Translational Cancer Research Network (NTRAC) Developing the Clinical Cancer Research Programme of Cancer Research UK. Achievements of the NHS Cancer Plan
A7.1 A7.2 A7.3 A7.4 A7.5 A7.6 A7.7
BASO Special Lecture – A8 Auditorium, 12:20–13:00 D Rosin
The Past – Surgical Oncology, The Future – Cancer Surgery
A8
Translational Research and the Role of Industry – A9 Auditorium, 14:00–15:20 K Sikora C Packer M Rawlins
Translational Cancer Research and the Drug Industry Horizon Scanning for Innovation in the NHS NICE and Cancer
A9.1 A9.2 A9.3
The Role of Surgeons in Cancer Research in the New NHS – B6 Umney Theatre, 14:00–15:30 T Allen-Mersh T Holme R Hardwick A Renehan
The Role of the Academic Department of Surgery in Future Cancer Research The Role of the Surgeon in a District General Hospital The Specialist Centre Cancer Surgeon: Best or Beast? Targeted Follow-Up After Curative Resection for Colorectal Cancer Improves Survival in a Cost-Effective Manner: Results Based on a Meta-Analysis
B6.1 B6.2 B6.3 B6.4
Paediatric Oncology – A10 Auditorium, 15:20–16:20 R Taylor T Eden
The SIOP/UKCCSG PNET-3 Study – Analysis of Outcome and Impact of Radio- A10.1 therapy (RT) Parameters (2 abstracts combined) Can Children Show us the Way? A10.2
The Annual Scientific Meeting of the BOA in Association with BASO
Cancer Research in the New NHS Robinson College, Cambridge Sunday 1st – Tuesday 3rd September, 2002
ABSTRACTS ACCEPTED FOR ORAL PRESENTATION Monday 2nd September 2002 The Challenge for Cancer in the Next Decade – A1 Auditorium, 09:00–10:00 R Black Progress in Cancer in the United Kingdom P Boyle Progress in Cancer in Europe: Challenges for the Next Decade
A1.1 A1.2
Proffered Papers – A2 Auditorium, 10:00–11:00 T Maughan N Lester G Laking D Routsis
How Does Investment in Research Networks Affect Cancer Research Activity? Establishing National Cancer Research Networks – Organisation, Structure and Impact ‘‘REFSARCH’’, A Test of the Tests for Cancer Hypoxia Measuring the Impact of New Radiotherapy Technologies on Treatment Times
A2.1 A2.2 A2.3 A2.4
An Integrated Information Environment for Translational Cancer Research Trials and Tribulations of Clinical Research: The Multi-Professional Team Approach Out Patient Site Specialist Nurses Improve Clinical Trial Recruitment A Model of Linear Accelerator Capacity
B1.1 B1.2 B1.3 B1.4
Proffered Papers – B1 Umney Theatre, 10:00–11:00 S Nagl H Moore S Khanduri N Burnet
Ethics: The Patient’s Role in Cancer Research – A3 Auditorium, 11:30–13:00 R Thomas M Robling J Tobias M King M Baum
Increasing User Involvement in Clinical Trials – Validating Patient Preference as a Legitimate Endpoint? Collecting Data for Disease Registries Without Patient Consent: What Do The Public Think? Research Governance – What Does the Cancer Clinician Need to Know About it? The Patient’s Contribution to Cancer Research The Patient’s Role in Cancer Research
A3.1
Should Primary Colorectal Cancer Excision be Avoided in Patients with Liver Metastases? The MRC Myeloma VII Trial of Standard Versus Intensive Treatment in Patients <65 Years of Age with Multiple Myeloma Randomised Trial of Standard 2D Radiotherapy (RT) Versus 3D Intensity Modulated Radiotherapy (IMRT) in Patients Prescribed Breast Radiotherapy A National Overview of Lung Cancer Surgery in Scotland
B2.1 B2.2
A3.2 A3.3 A3.4 A3.5
Proffered Papers – B2 Umney Theatre, 11:30–12:30 A Hanna-Morris G Morgan J Yarnold A Kirk
B2.3 B2.4
S34 New Technologies – A4 Auditorium, 14:00–16:00 C Caldas M van de Vijver D Miles C Nutting P Price T McCullough
Molecular Profiling in Cancer Care Microarray Analysis in Breast Cancer Targeted Systemic Therapies for Cancer New Technology in Radiation Oncology PET Scanning in Oncology When is PT-PCR Identification of Circulating Tumour Cells in Patients Undergoing Primary Colorectal Cancer Resection Most Predictive of Recurrence?
A4.1 A4.2 A4.3 A4.4 A4.5 A4.6
MRI Scanning in Breast Cancer Screening The ProtecT Study Should We Try To Screen for Lung Cancer? A Cohort Study into the Symptoms of Colorectal Cancer Using a General Practice Database 2% of Men With Early Onset Prostate Cancer Harbour Deleterious Germline Mutations in the BRCA2 Gene
B3.1 B3.2 B3.3 B3.4
Talking About Randomised Clinical Trials: An Interactive Workshop Describing Randomisation: Patients’ and Public’s Preferences Compared with Clinicians Practice
C1.1 C1.2
Prevention and Screening – B3 Umney Theatre, 14:00–15:30 R Warren F Hamdy M Meurs R Lawrenson R Eeles
B3.5
Talking About Trials – C1 Breakout Room 1, 14:00–16:00 L Fallowfield V Jenkins
NCRI Breast Cancer Workshop – A5 Auditorium, 16:30–17:45 J Stefoski-Mikeljevic J Yarnold P Hopwood I Kunkler
Does Postoperative Radiotherapy Delay in Breast Cancer Matter? Fractionation Sensitivity of Change in Breast Appearance after Radiotherapy for Early Breast Cancer: Long-Term Results of a Randomised Trial Quality of Life (QL) in Women Treated for Early Stage Breast Cancer Entering the START (Standardisation of Breast Radiotherapy) Trial PRIME – Trial Postoperative Radiotherapy in Low Risk Elderly Patients: SUPREMO – Selective Use of Postoperative Radiotherapy after Mastectomy in Intermediate Risk Breast Cancer Patients (2 abstracts combined)
A5.1 A5.2
Magnetic Resonance Imaging and Rectal Cancer European Equivalence Study (The M.E.R.C.U.R.Y. Study) The Use of the Pelican Surgical Training Programme to Improve Outcomes for Rectal Cancer in Trent Region The Teseract Trial: Target Selected Randomised Trial of Novel Therapies in Colorectal Cancer
B4.1
A5.3 A5.4
NCRI Colorectal Workshop – B4 Umney Theatre, 16:30–17:30 I Daniels N Armitage T Maughan
B4.2 B4.3
NCRI Lung Cancer Workshop – C2 Venue: Breakout Room 1, 16:30–18:00 M Saunders M Hatton R Stephens
M Hatton E Denholm
CHARTWEL with Neo-Adjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) A Randomised Trial of Megesterol Acetate and Prednisolone for Anorexia/Weight Loss in Patients with Lung Cancer and Mesothelioma The Big Lung Trial (BLT): Determining the Value of Cisplatin-Based Chemotherapy for all Patients with Non-Small Cell Lung Cancer (NSCLC). Preliminary Results in the Supportive Care Setting A Proposed Randomised Phase III Study of Induction Chemotherapy and CHARTWEL versus CHART Alone in Locally Advanced Non-Small Cell Lung Cancer The MARS (Mesothelioma and Radical Surgery) Trial
C2.1 C2.2 C2.3
C2.4 C2.5
S35 NCRI Urology Workshop – D1 Breakout Room 2, 16:30–17:30 E Hall M Leahy
R Huddart
A Phase III Randomised Trial of Post-Radiotherapy Intermittent Androgen Suppression (IAS) for Prostate Cancer Patients with Rising PSA – Survey of Interest The EMI Study: A Regional Feasibility Study for a Randomised Trial of Adjuvant Chemotherapy Following Definitive Treatment for Transitional Cell Carcinoma of the Bladder BC2001 – A Randomised Trial of Chemo-Radiotherapy in Bladder Cancer
D1.1 D1.2
D1.3
Tuesday 3rd September 2002 Educational Workshop – A6 Auditorium, 08:00–09:00 M Parmar
Trial Design
A6
Adjuvant Chemotherapy in Elderly Patients with Breast Cancer
B5
Educational Workshop – B5 Umney Theatre, 08:00–09:00 B Leonard
Cancer Research in the UK – a Blueprint for the Future? – A7 Auditorium, 09:00–12:20 R Hamilton A Spaull L O’Toole P Selby D Kerr R Souhami M Richards
The NHS Strategy for Cancer Research Supporting Cancer Research in Scotland NCRI Strategy and Future Plans The National Cancer Research Network – Scientific Opportunities National Translational Cancer Research Network (NTRAC) Developing the Clinical Cancer Research Programme of Cancer Research UK. Achievements of the NHS Cancer Plan
A7.1 A7.2 A7.3 A7.4 A7.5 A7.6 A7.7
BASO Special Lecture – A8 Auditorium, 12:20–13:00 D Rosin
The Past – Surgical Oncology, The Future – Cancer Surgery
A8
Translational Research and the Role of Industry – A9 Auditorium, 14:00–15:20 K Sikora C Packer M Rawlins
Translational Cancer Research and the Drug Industry Horizon Scanning for Innovation in the NHS NICE and Cancer
A9.1 A9.2 A9.3
The Role of Surgeons in Cancer Research in the New NHS – B6 Umney Theatre, 14:00–15:30 T Allen-Mersh T Holme R Hardwick A Renehan
The Role of the Academic Department of Surgery in Future Cancer Research The Role of the Surgeon in a District General Hospital The Specialist Centre Cancer Surgeon: Best or Beast? Targeted Follow-Up After Curative Resection for Colorectal Cancer Improves Survival in a Cost-Effective Manner: Results Based on a Meta-Analysis
B6.1 B6.2 B6.3 B6.4
Paediatric Oncology – A10 Auditorium, 15:20–16:20 R Taylor T Eden
The SIOP/UKCCSG PNET-3 Study – Analysis of Outcome and Impact of Radio- A10.1 therapy (RT) Parameters (2 abstracts combined) Can Children Show us the Way? A10.2